These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
430 related articles for article (PubMed ID: 14979733)
1. Should the insulin resistance syndrome be treated in the elderly? Grant RW; Meigs JB Drugs Aging; 2004; 21(3):141-51. PubMed ID: 14979733 [TBL] [Abstract][Full Text] [Related]
2. Addressing the insulin resistance syndrome: a role for the thiazolidinediones. Zimmet P Trends Cardiovasc Med; 2002 Nov; 12(8):354-62. PubMed ID: 12536122 [TBL] [Abstract][Full Text] [Related]
4. Management of the metabolic syndrome. Grant RW; Meigs JB Panminerva Med; 2005 Dec; 47(4):219-28. PubMed ID: 16489321 [TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of metformin against insulin resistance parameters: sinking the iceberg. Zimmet P; Collier G Drugs; 1999; 58 Suppl 1():21-8; discussion 75-82. PubMed ID: 10576521 [TBL] [Abstract][Full Text] [Related]
6. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Nesto RW Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526 [TBL] [Abstract][Full Text] [Related]
7. Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. Després JP Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S53-61. PubMed ID: 14502101 [TBL] [Abstract][Full Text] [Related]
8. Nurse health and lifestyle modification versus standard care in 40 to 70 year old regional adults: study protocol of the Management to Optimise Diabetes and mEtabolic syndrome Risk reduction via Nurse-led intervention (MODERN) randomized controlled trial. Carrington MJ; Zimmet P BMC Health Serv Res; 2017 Dec; 17(1):813. PubMed ID: 29212477 [TBL] [Abstract][Full Text] [Related]
11. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Resmini E; Minuto F; Colao A; Ferone D Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513 [TBL] [Abstract][Full Text] [Related]
12. Pharmacologic therapy for cardiovascular risk reduction in patients with the metabolic syndrome. Gouni-Berthold I; Berthold HK Curr Pharm Des; 2014; 20(31):5025-38. PubMed ID: 24320031 [TBL] [Abstract][Full Text] [Related]
13. Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. Bulcão C; Ribeiro-Filho FF; Sañudo A; Roberta Ferreira SG Am J Cardiovasc Drugs; 2007; 7(3):219-24. PubMed ID: 17610348 [TBL] [Abstract][Full Text] [Related]
15. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus. Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197 [TBL] [Abstract][Full Text] [Related]
16. Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease. Fonseca VA Am J Cardiol; 2003 Aug; 92(4A):50J-60J. PubMed ID: 12957327 [TBL] [Abstract][Full Text] [Related]
17. Metformin and vascular protection: a cardiologist's view. Libby P Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S117-20. PubMed ID: 14502109 [TBL] [Abstract][Full Text] [Related]
18. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Krentz AJ; Bailey CJ Drugs; 2005; 65(3):385-411. PubMed ID: 15669880 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes. Rosenson RS; Reasner CA Curr Opin Cardiol; 2004 Sep; 19(5):480-7. PubMed ID: 15316457 [TBL] [Abstract][Full Text] [Related]
20. Approaches to prevention of cardiovascular complications and events in diabetes mellitus. Coccheri S Drugs; 2007; 67(7):997-1026. PubMed ID: 17488145 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]